Pharvaris Outlines 2026 Strategic Priorities

Rhea-AI Summary

Pharvaris (NASDAQ: PHVS) outlined 2026 priorities focused on late‑stage development and regulatory filings for oral deucrictibant for bradykinin‑mediated angioedema. Key milestones: topline CHAPTER‑3 prophylaxis data expected 3Q2026; NDA preparation for on‑demand HAE treatment targeted for filing in 1H2026 based on RAPIDe‑3 and RAPIDe‑2; RAPIDe‑3 met its primary and all secondary endpoints with median onset of symptom relief of 1.28 hours (p<0.0001). CREAATE pivotal study in AAE‑C1INH is enrolling; CHAPTER‑4 long‑term extension is ongoing; CHAPTER‑1 open‑label data showed mean on‑treatment monthly attack rate of 0.12. Corporate runway is estimated into 1H2027, and Pharvaris was added to the Nasdaq Biotechnology Index in Dec 2025.

Positive

• RAPIDe‑3 met primary and all secondary endpoints with median symptom relief in 1.28 hours
• NDA dossier preparation on track for filing in 1H2026
• Topline CHAPTER‑3 prophylaxis data anticipated in 3Q2026
• CHAPTER‑1 open‑label mean monthly on‑treatment attack rate 0.12 (up to ~34 months)
• Corporate cash runway estimated into 1H2027
• Added to the Nasdaq Biotechnology Index in Dec 2025

Negative

• CHAPTER‑3 planned enrollment of only ~81 participants (2:1 randomization)
• Recruitment for CREAATE and other studies remains ongoing, creating execution risk to timelines
• Estimated cash runway into 1H2027 may necessitate additional financing before commercialization

News Market Reaction

+0.81%

1 alert

+0.81% News Effect

On the day this news was published, PHVS gained 0.81%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

CHAPTER-3 enrollment: 81 participants Prophylaxis dose: 40 mg Treatment duration: 24 weeks +5 more

8 metrics

CHAPTER-3 enrollment 81 participants Planned randomized Phase 3 CHAPTER-3 HAE prophylaxis study size

Prophylaxis dose 40 mg Deucrictibant extended-release tablet once daily in CHAPTER-3/CHAPTER-4

Treatment duration 24 weeks Randomized treatment period in CHAPTER-3 Phase 3 prophylaxis study

Attack rate 0.12 attacks/month Mean monthly on-treatment HAE attack rate in CHAPTER-1 open-label extension

Onset of relief 1.28 hours Median time to onset of symptom relief with deucrictibant in RAPIDe-3

P-value RAPIDe-3 p<0.0001 Statistical significance for RAPIDe-3 primary and secondary endpoints

NDA filing window 1H2026 Anticipated U.S. NDA submission for on-demand treatment of HAE attacks

Cash runway 1H2027 Estimated cash runway into first half of 2027

Market Reality Check

Price: $25.65 Vol: Volume 293,830 is 13% abo...

normal vol

$25.65 Last Close

Volume Volume 293,830 is 13% above 20-day average 260,436. normal

Technical Price 25.89 is trading above 200-day MA at 20.87, reflecting a pre-news uptrend.

Peers on Argus

PHVS gained 3.56% while biotech peers were mixed: ARDX +6.1%, BHVN -5.12%, EWTX ...

PHVS gained 3.56% while biotech peers were mixed: ARDX +6.1%, BHVN -5.12%, EWTX -0.28%, CDTX +0.03%, MNKD -3.78%. The pattern points to a stock-specific move rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Pivotal trial data	Positive	+21.8%	RAPIDe-3 Phase 3 met primary and all secondary endpoints with strong efficacy.
Nov 12	Earnings update	Positive	+7.0%	Q3 2025 results with Phase 3 progress and extended cash runway into H1 2027.
Nov 10	Scientific data update	Positive	+4.8%	Presented long-term safety, efficacy, and biomarker assay data for deucrictibant.
Oct 23	Conference participation	Positive	-2.0%	Announced multiple oral and poster presentations at ACAAI 2025 meeting.
Aug 12	Earnings update	Positive	+1.6%	Q2 2025 results, strong cash position, and ongoing Phase 3 trial timelines.

Pattern Detected

Recent PHVS news — especially pivotal clinical and earnings updates — has typically coincided with positive next-day price reactions.

Recent Company History

Over the last six months, Pharvaris has repeatedly highlighted progress for deucrictibant. Positive topline RAPIDe-3 Phase 3 data on Dec 03, 2025 coincided with a 21.75% gain, while Q3 2025 results on Nov 12, 2025 and Q2 2025 on Aug 12, 2025 also saw shares rise. Scientific meeting presentations in Nov 2025 and Oct 2025 focused on long‑term safety, efficacy, and assay validation. Today’s 2026 strategic priorities update extends that narrative with clear timelines toward NDA filing and additional Phase 3 readouts.

Market Pulse Summary

This announcement outlines Pharvaris’ 2026 roadmap: an HAE on-demand NDA filing targeted for 1H2026,...

Analysis

This announcement outlines Pharvaris’ 2026 roadmap: an HAE on-demand NDA filing targeted for 1H2026, CHAPTER-3 prophylaxis topline data in 3Q2026, and continued progress in AAE-C1INH via the CREAATE study. Long-term data from CHAPTER-1, including a mean attack rate of 0.12 attacks per month, and RAPIDe-3 efficacy with onset at 1.28 hours support the clinical profile. The company also reiterates an estimated cash runway into 1H2027, focusing attention on execution of late-stage trials and regulatory submissions.

Key Terms

phase 3, randomized, double-blind, placebo-controlled, open-label extension, new drug application (nda), +4 more

8 terms

phase 3 medical

"CHAPTER-3 is a randomized, double-blind, placebo-controlled Phase 3 study"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

randomized, double-blind, placebo-controlled medical

"CHAPTER-3 is a randomized, double-blind, placebo-controlled Phase 3 study"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

open-label extension medical

"Completed CHAPTER-1 (NCT05047185); final data recently presented. Final Results from the randomized portion and the long-term open-label extension"

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

new drug application (nda) regulatory

"Filing of U.S. New Drug Application (NDA) of deucrictibant for the on-demand treatment"

A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.

bradykinin b2 receptor antagonists medical

"developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs"

Bradykinin B2 receptor antagonists are drugs that block a specific cell receptor which responds to bradykinin, a natural molecule that causes blood vessels to leak, swell and send pain signals; blocking that receptor can reduce swelling, pain and inflammation. For investors, these drugs matter because successful candidates can address acute or chronic conditions with high unmet need, and their clinical trial results, safety profile and regulatory approvals strongly influence a company’s market value—think of the drug as putting a cap on a leaking pipe to stop costly damage.

hereditary angioedema medical

"such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor"

A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood‑control protein is missing or not working. Attacks can be unpredictable and sometimes life‑threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.

placebo medical

"once daily for 24 weeks. Pharvaris anticipates announcing topline data of CHAPTER-3 in the third quarter of 2026.Enrollment in CHAPTER-4 ... or placebo, once daily"

A placebo is an inactive pill, injection or procedure that looks and feels like the real treatment but contains no therapeutic ingredient, often called a sugar pill. Investors care because comparing a drug to a placebo reveals whether observed benefits come from the medicine itself or from expectation; clear superiority over placebo reduces regulatory and commercial risk, much like a blind taste test proves a new recipe really tastes better.

nasdaq biotechnology index financial

"Pharvaris recently added to Nasdaq Biotechnology Index (NBI)."

A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.

AI-generated analysis. Not financial advice.

• Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026
• Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026
• Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks
• Estimated cash runway into 1H2027

ZUG, Switzerland, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today outlined its strategic priorities for 2026.

“The readout of Pharvaris’ first pivotal Phase 3 study, RAPIDe-3, in December was the culmination of a decade of scientific rigor, operational and financial diligence, executional excellence, and, most importantly, community engagement and commitment,” said Berndt Modig, Chief Executive Officer of Pharvaris. “The data reported in December build upon Pharvaris’ legacy in HAE drug development, and we believe demonstrate deucrictibant’s potentially differentiated profile and potential to become a new standard of care for on-demand HAE treatment of attacks. Our team’s ability to conduct the most diverse Phase 3 on-demand study in HAE, by including previously underserved regions and subgroups, and improve upon the outcomes of the RAPIDe-1 Phase 2 study further bolsters our confidence in the clinical execution of the CHAPTER-3 prophylactic study, for which the timing of anticipated data readout has now been refined to the third quarter of 2026.”

2026 Strategic Priorities
Long-term Prophylaxis of HAE Attacks

• Topline data from CHAPTER-3 (NCT06669754) anticipated 3Q2026. CHAPTER-3 is a randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE. The study aims to enroll approximately 81 participants randomized in a 2:1 ratio to receive deucrictibant extended-release tablet (40 mg), which is the intended commercial dosage, or placebo, once daily for 24 weeks. Pharvaris anticipates announcing topline data of CHAPTER-3 in the third quarter of 2026.
• Enrollment in CHAPTER-4 (NCT06679881) progressing as planned. CHAPTER-4 is a long-term, open-label extension study of orally administered deucrictibant extended-release tablet (40 mg/day) for the prophylactic treatment of HAE attacks. The goal of the study is to evaluate the long-term safety and effectiveness of deucrictibant extended-release tablet in the prophylactic treatment of HAE attacks.
• Completed CHAPTER-1 (NCT05047185); final data recently presented. Final Results from the randomized portion and the long-term open-label portion of the study demonstrated that deucrictibant was well tolerated for up to approximately three years. The mean rate of HAE attacks was reduced by deucrictibant within the first week of treatment and remained low for up to approximately 34 months, with an overall mean monthly on-treatment attack rate of 0.12 throughout the completed open-label extension portion of the study.
  

On-demand Treatment of HAE Attacks

• RAPIDe-3 (NCT06343779) met primary endpoint and all secondary efficacy endpoints with statistical significance. Outcomes from RAPIDe-3, a pivotal global Phase 3 study evaluating orally administered deucrictibant immediate-release capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), confirming the potential of deucrictibant’s differentiated profile for the on-demand treatment of HAE attacks. The primary endpoint, median time to onset of symptom relief, was achieved in 1.28 hours, significantly faster versus placebo (p<0.0001), and deucrictibant was well tolerated. Pharvaris plans to present additional efficacy, safety, and patient experience data at upcoming medical congresses.
• Filing of U.S. New Drug Application (NDA) of deucrictibant for the on-demand treatment of HAE attacks anticipated 1H2026. Pharvaris is preparing the dossier for deucrictibant’s NDA filing. The data from RAPIDe-3 and RAPIDe-2 will serve as the basis for marketing authorization applications, which are planned to be filed starting in the first half of 2026.

Clinical Development of Deucrictibant in AAE-C1 INH

• CREAATE (NCT06669754) study progressing as planned. Pharvaris initiated CREAATE, a global, pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks, in November 2025. CREAATE assesses the efficacy and safety of deucrictibant in people living with AAE-C1INH. In part 1 of CREAATE, participants receive either deucrictibant extended-release tablet (40 mg) or placebo once daily for the prophylactic treatment of AAE-C1INH attacks. In part 2 of CREAATE, participants treat two attacks in a cross-over fashion, one attack with deucrictibant immediate-release capsule (20 mg) and one with placebo according to a randomized treatment sequence, for the on-demand treatment of AAE-C1INH attacks. Part 3 of CREAATE is the open-label extension portion of the study assessing the long-term safety and effectiveness of deucrictibant immediate-release capsule (20 mg) for on-demand treatment.
  

Business Updates
Corporate

• Cash runway into 1H2027. Pharvaris remains diligent in its operational management and is focusing on late-stage clinical development programs and commercial preparedness for the potential launch of deucrictibant.
• Pharvaris recently added to Nasdaq Biotechnology Index (NBI). In December 2025, Pharvaris was added to the NBI. Companies in the NBI must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.

Upcoming Participation at Investor Conferences

• Oppenheimer 36th Annual Healthcare Life Sciences Conference. Virtual, February 25-26, 2026.
  • Format: Fireside Chat
    Date, time: Thursday, February 26, 2026, 9:20-9:50 a.m. EST
• The Citizens Life Sciences Conference. Miami, FL, March 10-11, 2026.
  • Format: Fireside Chat
    Date, time: Tuesday, March 10, 2026, 11:20 a.m. EST
• Leerink Global Healthcare Conference 2026. Miami, FL, March 8-11, 2026.
  • Format: Fireside Chat
    Date, time: Wednesday, March 11, 2026, 9:20 a.m. EST

Live audio webcasts of the presentations will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. The audio replays will be available on Pharvaris’ website for 30 days following the presentation.

Upcoming Presentations at Medical Congresses

• Western Society of Allergy, Asthma & Immunology (WSAAI) 63^rd Annual Scientific Session. Wailea, HI, February 1-5, 2026. Details of the accepted presentation at WSAAI are as follows:
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
    Presenter: Michael E. Manning, M.D.
    Date, time: Wednesday, February 4, 2026, 7:00-8:00 a.m. HST (12:00-1:00 p.m. EST) and 11:30 a.m.-12:00 p.m. HST (4:30-5:00 p.m. EST)
• American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting. Philadelphia, PA, February 27-March 2, 2026. Details for the accepted presentations at AAAAI are as follows:
  • Title: A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema
    Presenter: Evangelia Pardali, Ph.D.
    Poster Number: 078
    Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
  • Title: Content Validity of the Angioedema syMptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks
    Presenter: Teresa Caballero, M.D., Ph.D.
    Poster Number: 154
    Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
  • Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
    Presenter: Michael E. Manning, M.D.
    Poster Number: 159
    Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
  • Title: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study
    Presenter: Marc A. Riedl, M.D., M.S.
    Featured Poster Number: 831
    Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
    Presenter: John Anderson, M.D.
    Featured Poster Number: 832
    Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
  • Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
    Presenter: Zhi-Yi Zhang, Ph.D.
    Featured Poster Number: 834
    Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
    

The posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.

About Deucrictibant
Deucrictibant is a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist currently in clinical development. Deucrictibant is being investigated for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks if/when they occur by inhibiting bradykinin signaling through the bradykinin B2 receptor. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment. Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration, the European Commission, and Swissmedic.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing global marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.

Forward-Looking Statements
This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words “believe,” “anticipate,” “expect,” “estimate,” “may,” “could,” “should,” “would,” “will,” “intend” and similar expressions. These forward-looking statements are based on management’s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris’ actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, RAPIDe-3, and CHAPTER-1 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials, such as CHAPTER-3, and CREAATE; the timing and outcome of regulatory approvals, including the timing and outcome of our planned submission of an NDA with the FDA in the first half of 2026 for the on-demand treatment of acute attacks of HAE; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act); our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; changes and uncertainty in general market, political and economic conditions, including as a result of inflation and geopolitical conflicts; changes in regulations and customs, tariffs and trade barriers; and the other factors described under the headings “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3. Key Information—D. Risk Factors” in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris’ views as of any date subsequent to the date of this press release.

Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

FAQ

When will Pharvaris (PHVS) announce topline CHAPTER‑3 prophylaxis data?

Topline data from CHAPTER‑3 are anticipated in 3Q2026.

What is Pharvaris’ timeline for filing an NDA for deucrictibant (PHVS) for on‑demand HAE?

Pharvaris is preparing the NDA dossier and expects to begin filings in 1H2026 using RAPIDe‑3 and RAPIDe‑2 data.

What were the key results of the RAPIDe‑3 study for PHVS deucrictibant?

RAPIDe‑3 met primary and all secondary endpoints; median time to onset of symptom relief was 1.28 hours (p<0.0001).

How long is Pharvaris’ (PHVS) reported cash runway?

Pharvaris estimates its corporate cash runway into 1H2027.

What is the design and size of CHAPTER‑3 for PHVS deucrictibant prophylaxis?

CHAPTER‑3 is a randomized, double‑blind, placebo‑controlled Phase 3 study enrolling approximately 81 participants randomized 2:1 to deucrictibant 40 mg daily or placebo for 24 weeks.

Is Pharvaris (PHVS) studying deucrictibant in acquired angioedema (AAE‑C1INH)?

Yes; the CREAATE pivotal Phase 3 study in AAE‑C1INH was initiated in Nov 2025 and is currently progressing with enrollment.